Skip to main content

Table 3 Hazard ratios for overall survival and severe kidney toxicities ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Covariate

 

Hazard ratio (95% CI)*

P Value

Overall survival

   

Gender

(male vs. females)

0.97 (0.74-1.28)

0.84

Age

(per year)

1.004 (0.99-1.02)

0.49

Duration of Disease

(per year)

0.98 (0.94-1.02)

0.30

Previous Surgery

(vs. no surgery)

0.62 (0.45-0.84)

0.002

Previous Systemic Therapies

(vs. no systemic therapies)

1.48 (1.08-2.01)

0.014

Previous Radiation

(vs. no radiation)

0.93 (0.64-1.36)

0.71

Single Metastasis

(vs. multiple metastases)

0.66 (0.26-1.35)

0.26

Liver Metastases

(vs. no liver metastases)

1.45 (0.86-2.44)

0.17

Bone Metastases

(vs. no bone metastases)

1.57 (1.10-2.23)

0.013

Tumor Uptake Score 2

(vs. Uptake Score 1)

0.70 (0.31-1.61)

0.40

Tumor Uptake Score 3

(vs. Uptake Score 1)

0.40 (0.18-0.91)

0.028

Low Dose [90Y-DOTA]-TOC

(vs. High Dose)

0.40 (0.17-0.93)

0.03

Intermediate Dose [90Y-DOTA]-TOC

(vs. High Dose)

0.64 (0.38-1.06)

0.08

Severe Kidney Toxicity

   

Gender

(male vs. females)

0.62 (0.33-1.18)

0.14

Age

(per 10 years)

0.99 (0.96-1.02)

0.64

Baseline Glomerular Filtration Rate

(per 10 mL/min/1.73 m 2 )

1.23 (1.09-1.39)

0.001

Low Dose [90Y-DOTA]-TOC

(vs. High Dose)

0.54 (0.20-1.43)

0.21

Intermediate Dose [90Y-DOTA]-TOC

(vs. High Dose)

0.32 (0.11-0.88)

0.027

  1. *Estimates for each co-variable have been adjusted for histology as a categorical co-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other co-variables listed.